PolyPeptide Group AG (SWX:PPGN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 1.31B +95.9% |
| Revenue (ttm) | 362.47M +15.6% |
| Net Income | -19.71M |
| EPS | -0.60 |
| Shares Out | 33.01M |
| PE Ratio | n/a |
| Forward PE | 53.69 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 45,171 |
| Open | 38.50 |
| Previous Close | 38.75 |
| Day's Range | 38.50 - 39.75 |
| 52-Week Range | 19.62 - 41.70 |
| Beta | 1.03 |
| Analysts | Buy |
| Price Target | 38.50 (-2.65%) |
| Earnings Date | Aug 13, 2026 |
About PolyPeptide Group AG
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, ... [Read more]
Full Company ProfileFinancial Performance
In 2025, PolyPeptide Group AG's revenue was 389.33 million, an increase of 15.60% compared to the previous year's 336.79 million. Losses were -21.17 million, 8.20% more than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for PPGN stock is "Buy." The 12-month stock price target is CHF 38.50, which is a decrease of -2.65% from the latest price.
News
PolyPeptide price target raised to CHF 38 from CHF 35 at Berenberg
Berenberg analyst Estelle Betrisey raised the firm’s price target on PolyPeptide (PLYGF) to CHF 38 from CHF 35 and keeps a Buy rating on the shares.
PolyPeptide price target raised to CHF 40 from CHF 33 at Barclays
Barclays raised the firm’s price target on PolyPeptide (PLYGF) to CHF 40 from CHF 33 and keeps an Overweight rating on the shares.
PolyPeptide is attracting takeover interest from EQT, KKR, Bloomberg says
PolyPeptide (PLYGF) Group is attracting private equity takeover interest, with EQT (EQBBF), KKR (KKR), and Advent among suitors looking into a potential acquisition of the company, Dinesh Nair, Allegr...
PolyPeptide Group AG Earnings Call Transcript: H2 2025
2025 saw 16% revenue growth and a sharp EBITDA margin improvement, driven by metabolic therapeutics and capacity expansions. 2026 guidance targets 20%-25% revenue growth and mid to high teens EBITDA margin, with strong customer prepayments and no equity raise planned.
PolyPeptide Group AG Earnings release: H2 2025
PolyPeptide Group AG released its H2 2025 earnings on March 12, 2026, summarizing the period's financial results.
PolyPeptide Group AG Annual report: H2 2025
PolyPeptide Group AG has published its H2 2025 annual report on March 12, 2026.
PolyPeptide Group AG Slides: H2 2025
PolyPeptide Group AG has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 12, 2026.
PolyPeptide price target lowered to CHF 33 from CHF 35 at Barclays
Barclays lowered the firm’s price target on PolyPeptide (PLYGF) to CHF 33 from CHF 35 and keeps an Overweight rating on the shares.
PolyPeptide Group AG Earnings Call Transcript: H1 2025
Revenue grew 24% year-over-year in H1 2025, driven by commercial metabolics and strong cash flow. Guidance for 2025 was raised, with EBITDA margin expected at 8–12% and CapEx increased to $100 million. Capacity expansions and market momentum support confidence in 2028 targets.
PolyPeptide Group AG Quarterly report: H1 2025
PolyPeptide Group AG has published its H1 2025 quarterly earnings report on August 12, 2025.
PolyPeptide Group AG Slides: H1 2025
PolyPeptide Group AG has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 12, 2025.